Johnson & Johnson (NYSE:JNJ) Holdings Trimmed by Fishman Jay A Ltd. MI

Fishman Jay A Ltd. MI trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 17.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,844 shares of the company’s stock after selling 5,883 shares during the quarter. Fishman Jay A Ltd. MI’s holdings in Johnson & Johnson were worth $4,027,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in JNJ. AMF Tjanstepension AB increased its stake in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $209,000. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $213,000. Wedge Capital Management L L P NC boosted its stake in Johnson & Johnson by 2.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after purchasing an additional 86 shares during the period. Finally, Creative Planning raised its stake in Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after purchasing an additional 41,082 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.7 %

Shares of Johnson & Johnson stock opened at $156.20 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a 50 day moving average price of $147.73 and a two-hundred day moving average price of $156.01. The stock has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business posted $2.29 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.18%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

Several analysts have recently commented on the company. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.